IPHA - Innate Pharma SA

QQQ $ 598.23 $ -2.23 (-0.37 %)

DIA $ 458.84 $ -3.15 (-0.68 %)

SPY $ 658.90 $ -4.53 (-0.68 %)

TLT $ 91.49 $ 0.68 (0.75 %)

GLD $ 401.79 $ 9.06 (2.34 %)

Previous Close

$ 2.14

Open

$ 2.21

Bid

$ 1.87 x 179

Ask

$ 2.48 x 250

Day's Range

$ 2.13 - $ 2.28

52 Week Range

$ 1.29 - $ 3.51

Volume

18,622

Average Volume

Market Cap

179.4M

Beta (5Y Monthly)

$ 0.86

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 12:09:03

12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 12:09:34

this-progressive-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday

This Progressive Analyst Is No Longer Bull...
09/18/2025 14:00:34

alphabet-to-rally-more-than-14-here-are-10-top-analyst-forecasts-for-thursday

Alphabet To Rally More Than 14%? Here Are ...
09/18/2025 12:16:40

Leerink Partners Downgrades Innate Pharma ...
09/18/2025 11:11:32

Leerink Partners analyst Daina Graybosch downgrades Innate Pharma (NASDAQ:IPHA) from Outperform to Market Perform and lowers...

HC Wainwright & Co. Downgrades Innate Phar...
09/18/2025 10:23:09

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Innate Pharma (NASDAQ:IPHA) from Buy to Neutral.

Earnings Scheduled For September 17, 2025
09/17/2025 08:32:11

Innate Pharma H1 EPS $(0.28) Up From $(0.3...
09/17/2025 05:50:37

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.28) per share. This is a 16.76 percent increase over losses of $(0...

12 Health Care Stocks Moving In Monday's P...
07/28/2025 12:08:27

12 Health Care Stocks Moving In Friday's P...
07/18/2025 12:07:40

$innate-pharma-presents-iph6501-preclinical-data-at-eha-2025-highlighting-potential-in-relapsed-refractory-and-untreated-cd20-b-nhl$

Innate Pharma Presents IPH6501 Preclinical...
06/13/2025 06:28:24

Preclinical data from IPH6501, Innate's proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro...

Innate Pharma Highlights Long-Term Clinica...
05/23/2025 05:41:56

Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented a...

Innate Pharma Highlights Continued Oncolog...
05/19/2025 06:37:30

Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoidesTrial in Progress poster on IPH45...

Innate Pharma Announces Selection Of IPH65...
05/15/2025 07:03:00

Innate Pharma Reports Q1 Revenue Of €1.2M,...
05/13/2025 05:56:11

Innate Pharma Presents New Preclinical Dat...
04/29/2025 19:03:17

IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced sol...

french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit

French Drugmaker Sanofi Clocks 20% Q1 Prof...
04/24/2025 14:03:30

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 gu...

HC Wainwright & Co. Reiterates Buy on Inna...
04/24/2025 11:08:24

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and lowers the pric...

Innate Pharma Confirms €15M Capital Increa...
04/24/2025 05:51:16

Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeti...

Innate Pharma Regains SAR'579 Rights For A...
04/23/2025 05:45:35

Innate to regain its rights on CD123 targeting ANKET® SAR443579 (SAR'579) /IPH6101 currently in development for AMLPotentia...